•
Mar 31, 2024

Revvity Q1 2024 Earnings Report

Revvity reported a revenue of $650 million with a (4)% reported growth and GAAP EPS of $0.21.

Key Takeaways

Revvity announced its financial results for the first quarter of 2024, reporting a revenue of $650 million. The company's GAAP EPS was $0.21, and the adjusted EPS from continuing operations was $0.98. Revvity reaffirmed its full-year 2024 organic growth and adjusted EPS guidance.

Revenue of $650 million; (4)% reported growth; (3)% organic growth

First quarter GAAP EPS of $0.21; Adjusted EPS from continuing operations of $0.98

Reaffirms full year 2024 organic growth and adjusted EPS guidance

Life Sciences revenue was $303 million, a decrease of 8% year-over-year.

Diagnostics revenue was $347 million, flat year-over-year.

Total Revenue
$650M
Previous year: $675M
-3.7%
EPS
$0.98
Previous year: $1.01
-3.0%
Organic Revenue Growth
-3%
Gross Profit
$264M
Previous year: $436M
-39.5%
Cash and Equivalents
$998M
Previous year: $2.27B
-56.0%
Free Cash Flow
$130M
Previous year: $42.5M
+205.1%
Total Assets
$13.4B
Previous year: $14.6B
-8.2%

Revvity

Revvity

Revvity Revenue by Segment

Forward Guidance

The Company is updating its full year 2024 total revenue guidance to a range of $2.76-$2.82 billion to reflect recent changes in foreign currency exchange rates. The Company is also reaffirming its adjusted EPS guidance of $4.55-$4.75 and organic growth guidance of 1-3%.